Yasuo Matsuzawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasuo Matsuzawa has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Hiroki Wakabayashi
Division of Respiratory Medicine, Department of Internal Medicine Toho University Sakura Medical Center Sakura Chiba Japan
5 shared publications - Daiki Sakai
Division of Rheumatology, Department of Internal Medicine Toho University Sakura Medical Center Sakura Chiba Japan
4 shared publications - Kaichi Kaneko
Division of Rheumatology, Department of Internal Medicine Toho University Sakura Medical Center Sakura Chiba Japan
4 shared publications Sho Hayakawa
Department of Internal Medicine, Toho University Sakura Medical Center, Japan
4 shared publicationsHagino Rikitake
Department of Internal Medicine, Toho University Sakura Medical Center, Japan
3 shared publicationsTatsuo Kawashima
Department of Internal Medicine, Toho University Medical Center, Sakura Hospital, Japan
3 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (49) , e46238
Amikacin liposomal inhalation suspension versus injectable streptomycin in patients with refractory pulmonary Mycobacterium avium complex disease: A single-center, retrospective cohort study
Amikacin liposomal inhalation suspension (ALIS) and injectable streptomycin (SM) are aminoglycosides used in addition to guideline-based therapy (GBT) in patients with Mycobacterium avium complex lung disease (MAC-LD). However, no studies have compared the efficacy of ALIS and injectable SM in patients with refractory MAC-LD. The current study aimed to retrospectively compare the sputum culture conversion rates and the treatment continuation probability of ALIS and injectable SM in patients with refractory MAC-LD. This study included patients with refractory MAC-LD who were diagnosed with MAC-LD at the Department of Respiratory Medicine at Toho University Medical Center Sakura Hospital from April 2010 to May 2023, and who could not achieve negative sputum culture conversion after GBT for at least 6 months resulting in new treatment with ALIS or injectable SM. The medical records of the patients were retrospectively reviewed. Then, the sputum culture conversion rates up to 6 months and the treatment continuation probability up to 6 months between patients receiving ALIS and those receiving injectable SM were compared. Twenty-three patients with MAC-LD were eligible for present study. Eleven patients were treated with ALIS and 12 with injectable SM. Four (36%) patients treated with ALIS and 2 (17%) with injectable SM achieved negative sputum culture conversion, but there was no statistically significant difference between 2 groups ( P = .37). The continuation probability up to 6 months of the patients treated with ALIS was significantly higher than that of patients treated with injectable SM (two-tailed log-rank test hazard ratio: 0.058, 95% confidence interval: 0.018–0.185, P = .0001). The most common cause of injectable SM discontinuation was hospital visit difficulty. ALIS and injectable SM had similar sputum culture conversion rates. However, the former had a higher continuation probability than the latter.
- 5 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (49) , e46238
Open AccessAmikacin liposomal inhalation suspension versus injectable streptomycin in patients with refractory pulmonary Mycobacterium avium complex disease: A single-center, retrospective cohort study
Amikacin liposomal inhalation suspension (ALIS) and injectable streptomycin (SM) are aminoglycosides used in addition to guideline-based therapy (GBT) in patients with Mycobacterium avium complex lung disease (MAC-LD). However, no studies have compared the efficacy of ALIS and injectable SM in patients with refractory MAC-LD. The current study aimed to retrospectively compare the sputum culture conversion rates and the treatment continuation probability of ALIS and injectable SM in patients with refractory MAC-LD. This study included patients with refractory MAC-LD who were diagnosed with MAC-LD at the Department of Respiratory Medicine at Toho University Medical Center Sakura Hospital from April 2010 to May 2023, and who could not achieve negative sputum culture conversion after GBT for at least 6 months resulting in new treatment with ALIS or injectable SM. The medical records of the patients were retrospectively reviewed. Then, the sputum culture conversion rates up to 6 months and the treatment continuation probability up to 6 months between patients receiving ALIS and those receiving injectable SM were compared. Twenty-three patients with MAC-LD were eligible for present study. Eleven patients were treated with ALIS and 12 with injectable SM. Four (36%) patients treated with ALIS and 2 (17%) with injectable SM achieved negative sputum culture conversion, but there was no statistically significant difference between 2 groups ( P = .37). The continuation probability up to 6 months of the patients treated with ALIS was significantly higher than that of patients treated with injectable SM (two-tailed log-rank test hazard ratio: 0.058, 95% confidence interval: 0.018–0.185, P = .0001). The most common cause of injectable SM discontinuation was hospital visit difficulty. ALIS and injectable SM had similar sputum culture conversion rates. However, the former had a higher continuation probability than the latter.
- Open Access
- 14 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (46) , e45924
Differentiating respiratory syncytial virus pneumonia from interstitial lung disease associated with systemic sclerosis: A case report
Rationale: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in older adults. In systemic sclerosis, interstitial lung disease is a frequent, serious complication requiring immunosuppressive therapy. Differentiating RSV pneumonia from systemic sclerosis-associated interstitial lung disease (SSc-ILD) is essential for appropriate management and to avoid initiating immunosuppressive agents that may be harmful in cases of RSV pneumonia. Patient concerns: An 85-year-old woman with limited cutaneous systemic sclerosis and dementia presented with a 1-week history of nonproductive cough and fever. Diagnoses: Chest computed tomography (CT) showed bilateral consolidations, bronchial wall thickening, and mucus plugs, suggesting airway infection. However, both respiratory symptoms and CT findings worsened, and sputum and blood cultures remained negative. To differentiate SSc-ILD from viral infection, multiplex PCR testing (FilmArray) of a pharyngeal swab was performed, detecting RSV and confirming RSV pneumonia. Interventions: The patient was initially treated with intravenous ceftriaxone, then given prednisolone at 0.6 mg/kg/d after RSV was diagnosed. Outcomes: Her respiratory symptoms and CT findings improved, and she was discharged on day 16 with tapering corticosteroids. Lessons: Multiplex PCR is useful for detecting RSV pneumonia in patients with autoimmune diseases. Clinicians should be aware that RSV infection can occur in these patients and should consider RSV pneumonia as an important differential diagnosis of SSc-ILD.
- 14 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (46) , e45924
Open AccessDifferentiating respiratory syncytial virus pneumonia from interstitial lung disease associated with systemic sclerosis: A case report
Rationale: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in older adults. In systemic sclerosis, interstitial lung disease is a frequent, serious complication requiring immunosuppressive therapy. Differentiating RSV pneumonia from systemic sclerosis-associated interstitial lung disease (SSc-ILD) is essential for appropriate management and to avoid initiating immunosuppressive agents that may be harmful in cases of RSV pneumonia. Patient concerns: An 85-year-old woman with limited cutaneous systemic sclerosis and dementia presented with a 1-week history of nonproductive cough and fever. Diagnoses: Chest computed tomography (CT) showed bilateral consolidations, bronchial wall thickening, and mucus plugs, suggesting airway infection. However, both respiratory symptoms and CT findings worsened, and sputum and blood cultures remained negative. To differentiate SSc-ILD from viral infection, multiplex PCR testing (FilmArray) of a pharyngeal swab was performed, detecting RSV and confirming RSV pneumonia. Interventions: The patient was initially treated with intravenous ceftriaxone, then given prednisolone at 0.6 mg/kg/d after RSV was diagnosed. Outcomes: Her respiratory symptoms and CT findings improved, and she was discharged on day 16 with tapering corticosteroids. Lessons: Multiplex PCR is useful for detecting RSV pneumonia in patients with autoimmune diseases. Clinicians should be aware that RSV infection can occur in these patients and should consider RSV pneumonia as an important differential diagnosis of SSc-ILD.
- 18 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-8
Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study
Mepolizumab (MPZ) is an anti-interleukin-5 monoclonal antibody used to treat eosinophilic granulomatosis with polyangiitis (EGPA). This study aimed to compare the efficacy of MPZ and conventional treatment (CT) for EGPA after maintenance therapy initiation. In this retrospective, observational study, patients diagnosed with EGPA meeting these criteria were included: prednisolone ≤ 20 mg/day, Birmingham Vasculitis Activity Score (BVAS) < 10, and MPZ or new CT initiation ≥ 6 months after initial treatment were included (MPZ: n = 16; CT: n = 16). BVAS, relapse-free survival, absolute eosinophil count, cumulative glucocorticoids (GC) dose, and GC toxicity index (GTI) were evaluated for up to 12 months. Multivariable linear regression for BVAS and logistic regression for relapse at 12 months were performed, adjusting for age, gender, disease duration, and baseline eosinophil count. In the MPZ group, BVAS at 12 months significantly decreased, while BVAS tended to be lower in the MPZ than in the CT group at 12 months. Participants achieving BVAS = 0 significantly increased in the MPZ group at 12 months. Relapse rates tended to be lower in the MPZ group. Absolute eosinophil counts decreased in the MPZ compared with the CT group from 1 to 12 months. Cumulative GC dose and GTI significantly decreased in the MPZ group vs. CT group. In multivariable analyses, the use of MPZ was suggestive of lower BVAS and lower odds of relapse at 12 months compared with CT, although these differences were not statistically significant. MPZ could be a potential treatment option for reducing GC or improving residual symptoms in patients with EGPA.
- 18 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-8
Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study
Mepolizumab (MPZ) is an anti-interleukin-5 monoclonal antibody used to treat eosinophilic granulomatosis with polyangiitis (EGPA). This study aimed to compare the efficacy of MPZ and conventional treatment (CT) for EGPA after maintenance therapy initiation. In this retrospective, observational study, patients diagnosed with EGPA meeting these criteria were included: prednisolone ≤ 20 mg/day, Birmingham Vasculitis Activity Score (BVAS) < 10, and MPZ or new CT initiation ≥ 6 months after initial treatment were included (MPZ: n = 16; CT: n = 16). BVAS, relapse-free survival, absolute eosinophil count, cumulative glucocorticoids (GC) dose, and GC toxicity index (GTI) were evaluated for up to 12 months. Multivariable linear regression for BVAS and logistic regression for relapse at 12 months were performed, adjusting for age, gender, disease duration, and baseline eosinophil count. In the MPZ group, BVAS at 12 months significantly decreased, while BVAS tended to be lower in the MPZ than in the CT group at 12 months. Participants achieving BVAS = 0 significantly increased in the MPZ group at 12 months. Relapse rates tended to be lower in the MPZ group. Absolute eosinophil counts decreased in the MPZ compared with the CT group from 1 to 12 months. Cumulative GC dose and GTI significantly decreased in the MPZ group vs. CT group. In multivariable analyses, the use of MPZ was suggestive of lower BVAS and lower odds of relapse at 12 months compared with CT, although these differences were not statistically significant. MPZ could be a potential treatment option for reducing GC or improving residual symptoms in patients with EGPA.
- Open Access
- 29 August 2024
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (4) , 603-615
Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
Background The prognosis of patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer has improved significantly since the advent of EGFR tyrosine kinase inhibitors (EGFR-TKIs). We aimed to investigate the relationship between patient characteristics, EGFR genotype, therapeutic agents, and the prognosis of the patients with EGFR mutation-positive lung cancer. Methods This retrospective cohort study analyzed 198 Japanese patients with unresectable EGFR mutation-positive lung cancer who were treated with EGFR-TKIs at Toho University Sakura Medical Center from April 2006 to December 2021. Factors associated with overall survival (OS) were analyzed using Cox proportional hazards analysis. Results Patients who received osimertinib had a significantly longer OS than did those not receiving it (median OS, 36.2 versus 20.7 months; p < 0.001).There were significant differences in OS between patients with EGFR mutation who received osimertinib as first-line treatment, T790M-positive patients who received osimertinib as second- or later-line treatment, and those who did not receive it (median OS, 28.2 versus 40.2 versus 20.7 months; p = 0.003). However, in T790M-negative patients, no significant difference in OS was noted between those who did and did not receive osimertinib as post-treatment (median OS, 28.0 versus 40.0 months; p = 0.619). Multivariate Cox proportional hazards analysis showed that osimertinib treatment was associated with longer OS (hazard ratio, 0.480; 95% confidence interval, 0.326–0.707; p < 0.001). Conclusion The patients who were T790M-positive in the first-line treatment with first or second-generation EGFR-TKIs and were given osimertinib as the second or later line treatment had a better prognosis than the patients who were T790M-negative in the first-line treatment with first or second-generation EGFR-TKIs and could not receive osimertinib.
- 29 August 2024
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (4) , 603-615
Open AccessPrognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
Background The prognosis of patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer has improved significantly since the advent of EGFR tyrosine kinase inhibitors (EGFR-TKIs). We aimed to investigate the relationship between patient characteristics, EGFR genotype, therapeutic agents, and the prognosis of the patients with EGFR mutation-positive lung cancer. Methods This retrospective cohort study analyzed 198 Japanese patients with unresectable EGFR mutation-positive lung cancer who were treated with EGFR-TKIs at Toho University Sakura Medical Center from April 2006 to December 2021. Factors associated with overall survival (OS) were analyzed using Cox proportional hazards analysis. Results Patients who received osimertinib had a significantly longer OS than did those not receiving it (median OS, 36.2 versus 20.7 months; p < 0.001).There were significant differences in OS between patients with EGFR mutation who received osimertinib as first-line treatment, T790M-positive patients who received osimertinib as second- or later-line treatment, and those who did not receive it (median OS, 28.2 versus 40.2 versus 20.7 months; p = 0.003). However, in T790M-negative patients, no significant difference in OS was noted between those who did and did not receive osimertinib as post-treatment (median OS, 28.0 versus 40.0 months; p = 0.619). Multivariate Cox proportional hazards analysis showed that osimertinib treatment was associated with longer OS (hazard ratio, 0.480; 95% confidence interval, 0.326–0.707; p < 0.001). Conclusion The patients who were T790M-positive in the first-line treatment with first or second-generation EGFR-TKIs and were given osimertinib as the second or later line treatment had a better prognosis than the patients who were T790M-negative in the first-line treatment with first or second-generation EGFR-TKIs and could not receive osimertinib.
- Open Access
- 26 October 2023
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (1) , 43-52
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
Background The antifibrotic drugs, nintedanib and pirfenidone, inhibit the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF). Nintedanib also inhibits the onset of acute exacerbation and reduces the risk of all-cause mortality. However, their effectiveness in real-world practice remains unclear. Our study aimed to investigate the changes in forced vital capacity, survival period, causes of death, and risk factors for mortality in patients with IPF receiving antifibrotic drugs. Methods This retrospective study enrolled Japanese patients who visited Toho University Sakura Medical Center who were diagnosed with IPF and received antifibrotic drugs. Results We included 102 patients [mean age ± standard deviation (SD): 71.8 ± 7.5 years], of whom 76 were males. The decline in forced vital capacity (mean ± SD) during the antifibrotic therapy period was − 154 ± 259 mL/year, which was significantly lower than before the antifibrotic therapy period (− 484 ± 589 mL/year; n = 80, p = 0.003). Altogether, 52 deaths were confirmed, and the median survival time from antifibrotic therapy initiation was 38.0 months (95% confidence interval: 25.9–50.1 months). Acute exacerbation accounted for 9.6% of all deaths (95% confidence interval: 1.6–17.6). The decline in forced vital capacity during antifibrotic therapy was a risk factor for mortality. Conclusions In actual clinical practice in Japan, antifibrotic drugs suppressed the gradual decline in forced vital capacity, which is a risk factor for mortality. However, the median survival period remained poor at 38 months.
- 26 October 2023
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (1) , 43-52
Open AccessReal-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
Background The antifibrotic drugs, nintedanib and pirfenidone, inhibit the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF). Nintedanib also inhibits the onset of acute exacerbation and reduces the risk of all-cause mortality. However, their effectiveness in real-world practice remains unclear. Our study aimed to investigate the changes in forced vital capacity, survival period, causes of death, and risk factors for mortality in patients with IPF receiving antifibrotic drugs. Methods This retrospective study enrolled Japanese patients who visited Toho University Sakura Medical Center who were diagnosed with IPF and received antifibrotic drugs. Results We included 102 patients [mean age ± standard deviation (SD): 71.8 ± 7.5 years], of whom 76 were males. The decline in forced vital capacity (mean ± SD) during the antifibrotic therapy period was − 154 ± 259 mL/year, which was significantly lower than before the antifibrotic therapy period (− 484 ± 589 mL/year; n = 80, p = 0.003). Altogether, 52 deaths were confirmed, and the median survival time from antifibrotic therapy initiation was 38.0 months (95% confidence interval: 25.9–50.1 months). Acute exacerbation accounted for 9.6% of all deaths (95% confidence interval: 1.6–17.6). The decline in forced vital capacity during antifibrotic therapy was a risk factor for mortality. Conclusions In actual clinical practice in Japan, antifibrotic drugs suppressed the gradual decline in forced vital capacity, which is a risk factor for mortality. However, the median survival period remained poor at 38 months.
- Open Access
- 4 August 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (31) , e34533
Serum IgG4-negative IgG4-related disease with a cardiac mass: A case report
Rationale: Although IgG4-related disease (IgG4-RD) can affect various organs, its association with a cardiac mass is exceptionally rare. Here, we report a case of a woman with IgG4-RD and a cardiac mass and discuss 10 similar cases reported previously. Patient concerns: A 65-year-old woman was referred to our hospital for chest discomfort and back pain. Diagnoses: In accordance with the 2019 ACR/EULAR diagnostic criteria for IgG4-RD, she was diagnosed with IgG4-RD based on dense lymphocytic infiltration on histopathology, IgG/IgG4-positive cell ratio 10/hpf IgG4-positive cells on immunostaining, and paraspinal zone soft tissue lesions in the chest. Interventions: An external pacemaker was implanted for the complete atrioventricular block on the electrocardiogram. After the diagnosis of IgG4-RD, she was treated with glucocorticoids and rituximab. Outcomes: She remains under observation without disease recurrence. Lessons: IgG4-RD are usually treated with glucocorticoids; however, in cases of a cardiac mass, life-threatening complications may occur and surgery is often needed. Combination therapy with glucocorticoids and rituximab may be effective even in patients with IgG4-RD and cardiac mass, which may avoid the need of invasive treatments, such as surgery.
- 4 August 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (31) , e34533
Open AccessSerum IgG4-negative IgG4-related disease with a cardiac mass: A case report
Rationale: Although IgG4-related disease (IgG4-RD) can affect various organs, its association with a cardiac mass is exceptionally rare. Here, we report a case of a woman with IgG4-RD and a cardiac mass and discuss 10 similar cases reported previously. Patient concerns: A 65-year-old woman was referred to our hospital for chest discomfort and back pain. Diagnoses: In accordance with the 2019 ACR/EULAR diagnostic criteria for IgG4-RD, she was diagnosed with IgG4-RD based on dense lymphocytic infiltration on histopathology, IgG/IgG4-positive cell ratio 10/hpf IgG4-positive cells on immunostaining, and paraspinal zone soft tissue lesions in the chest. Interventions: An external pacemaker was implanted for the complete atrioventricular block on the electrocardiogram. After the diagnosis of IgG4-RD, she was treated with glucocorticoids and rituximab. Outcomes: She remains under observation without disease recurrence. Lessons: IgG4-RD are usually treated with glucocorticoids; however, in cases of a cardiac mass, life-threatening complications may occur and surgery is often needed. Combination therapy with glucocorticoids and rituximab may be effective even in patients with IgG4-RD and cardiac mass, which may avoid the need of invasive treatments, such as surgery.
- 1 October 2021
- Published by Elsevier in Clinica Chimica Acta
- Vol. 521, 278-284
High presepsin concentrations in bile and its marked elevation in biliary tract diseases: A retrospective analysis
- 1 October 2021
- Published by Elsevier in Clinica Chimica Acta
- Vol. 521, 278-284
High presepsin concentrations in bile and its marked elevation in biliary tract diseases: A retrospective analysis
- Open Access
Lower airway microbiota in patients with clinically suspected Mycobacterium avium complex lung disease
- Open Access
- 25 June 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 112-119
Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.
- 25 June 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 112-119
Open AccessClinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.